抗體部門
抗體藥物複合體5月3日∼4日
屬臨床開發後期階段的抗體藥物複合體(ADC)，對於充實性腫瘤與血液腫瘤雙方，呈現出有希望的治療效果。藉由特異性、效能、連接子技術、複合體部位設計、醫藥品的化學量與排列等參數的最適化，ADC達到大幅度的進化。本學會將介紹次世代ADC的設計與表現、活用從成功背後所進展開發的臨床候補所獲得最新知識的方法等。
第1天 | 第2天
5月3日, 星期四
12:00 pm Registration
1:30 Chairperson's Opening Remarks
Pamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals, Inc.
» 1:40 Featured Speaker
Lessons Learned from the Clinic – T-DM1 and Beyond
John Lambert, Ph.D., CSO, ImmunoGen, Inc.
Since 1999, a number of antibody-maytansinoid conjugates (AMCs) have entered clinical testing, with the most advanced of these, T-DM1 and SAR3419, attracting attention for their efficacy and tolerability profile. Lessons learned from earlier AMCs helped inform the design of these compounds, and this body of knowledge that can be applied to AMC design continues to expand and will be discussed.
|
» 2:10 Featured Speaker
The Development of ADCs at Seattle Genetics
Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine, Seattle Genetics
Antibody-drug conjugates (ADCs) represent an important class of new cancer therapeutics under development. The deceptively simple concept of targeted drug delivery has been an elusive goal for decades but has been realized with the approval of brentuximab vedotin (ADCETRIS).The current approach to designing empowered antibodies and testing them both pre-clinically and clinically will be discussed.
|
2:40 Sponsored Presentations (Opportunities Available)
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Clinical Case Study
Anne Bousseau, M.D., Head, Early Development Projects, Global Oncology, Sanofi-Aventis
4:30 Antibody-Drug Conjugates: Pre-Clinical Evaluation of a Novel Target
Andrew Simmons, Ph.D., Associate Director, Oncology, Takeda California
5:30-8:30 pm Recommended Dinner Short Course*
SC14 Antibody Conjugate Therapeutics: Potential and Challenges
*Separate registration required.
|
第1天 | 第2天
.jpg "Pharma-Bio Partnsering Forum")